Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macrogenetics and metabolomics of differential response to lecanemab in Alzheimer's disease
ChiCTR2500098225Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Shenzhen Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lecanemab in Alzheimer's disease (AD), sponsored by Southern Medical University Shenzhen Hospital. Primary endpoints: Blood routine index and Microbiological indicator. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2500098225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098225.